Navigating PD-1 Inhibitor Selection and Clinical Trial End Points

In “Navigating PD-1 Inhibitor Selection and Clinical Trial End Points,” the expert oncology pharmacists examined the following critical questions:

Why might clinicians assume similar efficacy across drugs within the same PD-1 inhibitor class?

What clinical end points, beyond overall survival, are commonly used to evaluate immunotherapy efficacy?

Led by the moderator, Megan May, PharmD, BCOP, FHOPA, FAPO, the expert oncology pharmacists examined the perceived class effect of PD-1 inhibitors and the pharmacological similarities that lead some clinicians to interchange these agents. The panelists discussed how, although these drugs share similar mechanisms, differences in clinical trial populations and data maturity—specifically between the RUBY (NCT03981796) and NRG-GY018 (NCT03914612) trials—warrant careful selection of individual agents. The experts also explored secondary end points, such as progression-free survival, objective response rate, and duration of response, emphasizing that stable disease can be a significant clinical win. Furthermore, the panel highlighted the critical role of monitoring quality of life and managing grade 3 or 4 toxicities during long-term maintenance therapy.

Throughout the conversation, the panelists offered a comprehensive reflection on the field and the factors that may shape clinicians’ approach to care moving forward.

In the next episode, “Clinical Practice Insights: Pharmacists Managing Advanced Endometrial Cancer,” the panelists continue their discussion of endometrial cancer and highlight the need for universal biomarker testing and the specific patient characteristics, such as histology and comorbidities, that influence treatment selection.